Ibrance (Palbociclib)

Palbociclib is a medicine used to treat a type of breast cancer that has spread. It works by blocking proteins that cancer cells need to divide and grow. It's taken as a pill by mouth, usually together with hormone therapy.

Brand names:Ibrance
Medication

What people taking Ibrance (Palbociclib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Ibrance (Palbociclib) for Breast Cancer?

NameHow it went

About Ibrance (Palbociclib)

What It's For

Palbociclib, sold as Ibrance, is a prescription pill used to treat advanced breast cancer, including cancer that has spread to other parts of the body (metastatic). It is used for cancers that are hormone receptor-positive (HR-positive), meaning estrogen or progesterone helps fuel their growth. It is always given together with other cancer treatment rather than on its own. For HR-positive cancers that are HER2-negative (they do not carry extra amounts of a growth protein called HER2), palbociclib is approved in adults with an aromatase inhibitor, a hormone-blocking pill such as letrozole, as the first hormone-based treatment for advanced disease. It is also approved with fulvestrant, an injected hormone therapy, after the cancer has grown during earlier hormone treatment. When the cancer has a change in the PIK3CA gene, found with an FDA-authorized test, and came back during or after hormone therapy given following surgery, palbociclib can be combined with inavolisib (Itovebi), a targeted pill, and fulvestrant. For cancers that are both HR-positive and HER2-positive, palbociclib can be added to ongoing maintenance treatment once initial chemotherapy has brought the disease under control. That maintenance combines it with trastuzumab, with or without pertuzumab (antibody drugs that target HER2), and hormone therapy. Palbociclib belongs to a group of medicines called CDK4/6 inhibitors, which also includes ribociclib (Kisqali) and abemaciclib (Verzenio). It is not approved for early-stage breast cancer after surgery: a large trial found that adding it to hormone therapy at that stage did not significantly lower the chance of the cancer returning.

How It Works

Cells divide in a tightly controlled sequence called the cell cycle. Two enzymes, cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), work like a switch that lets a cell move from its resting phase into copying its DNA and dividing. In HR-positive breast cancer, the growth signals that drive the tumor, including those from estrogen, run through this switch. Palbociclib blocks CDK4 and CDK6, holding cancer cells at that checkpoint so they divide less. Hormone therapy weakens the estrogen signal further upstream, and in laboratory studies the two together stopped breast cancer cells from growing more effectively than either did alone. That is why palbociclib is paired with hormone therapy. The drug also slows healthy cells that divide quickly, especially the bone marrow cells that make white blood cells, which explains its most common side effect.

Dosage & Administration

Palbociclib is taken by mouth once a day for 21 days in a row, followed by 7 days off, making a 28-day cycle. The usual starting dose is 125 mg. Tablets can be taken with or without food, while the capsule form must be taken with food. Take it at about the same time each day and swallow it whole, without chewing, crushing, splitting or opening it. Do not take a tablet that is broken or cracked. If you miss a dose or vomit after taking one, do not take an extra dose; take the next one at the usual time. The medicines paired with palbociclib follow their own schedules: aromatase inhibitors are daily pills, and fulvestrant is given as an injection. Women who have not gone through menopause, or are going through it, also receive an LHRH (luteinizing hormone-releasing hormone) agonist, an injection that stops the ovaries from making estrogen. Men taking palbociclib may be offered one as well. Dose changes are common. In the main trials, about a third of people had their dose lowered because of side effects. The care team may pause treatment, delay the next cycle or step the dose down to 100 mg or 75 mg, most often because white blood cell counts have dropped.

Side Effects

The most common effect is a drop in neutrophils, the white blood cells that fight bacterial infections. It happened in about 8 of 10 people in the main trials. It usually shows up on blood tests rather than being felt, tends to appear within the first few weeks, and episodes of a significant drop typically last about a week. Other common effects include tiredness, nausea, mouth sores, diarrhea, hair thinning, infections, anemia (low red blood cells, which can add to tiredness) and lower platelet counts. Serious infection is uncommon, but a low neutrophil count makes it harder to fight one. Call the care team right away for a fever, chills or other signs of infection, or for unusual bleeding or bruising. Rarely, palbociclib causes inflammation of the lungs (pneumonitis), which has been severe or fatal in a small number of people. Report a new or worsening cough, shortness of breath or other breathing problems to the care team right away, so treatment can be paused and the cause checked.

Interactions & Warnings

Palbociclib is broken down mainly by a liver enzyme called CYP3A, so medicines and foods that affect this enzyme change how much drug reaches the blood. Avoid grapefruit and grapefruit juice, which can raise palbociclib levels. Some antibiotics (such as clarithromycin), antifungal pills (such as itraconazole, ketoconazole, posaconazole and voriconazole) and HIV medicines (such as ritonavir) raise levels strongly; if one cannot be avoided, the palbociclib dose is lowered. Other medicines lower levels and may make it less effective, including rifampin (an antibiotic used for tuberculosis), the seizure medicines phenytoin and carbamazepine, and the herbal supplement St. John's wort. Palbociclib can also raise the levels of certain medicines whose safe dose range is narrow, such as the transplant drugs tacrolimus and cyclosporine and the opioid fentanyl. Tell the oncology team and pharmacist about every medicine and supplement you take, including new prescriptions from other doctors. Palbociclib can harm a developing baby. Women who could become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose, and men with partners who could become pregnant should use it during treatment and for at least 3 months after. Tell the care team promptly about a known or suspected pregnancy. Do not breastfeed during treatment or for 3 weeks after the last dose.

What to Expect

Palbociclib is used to control advanced breast cancer for as long as possible, not to cure it. In the main trial of people starting it with letrozole as their first treatment for advanced disease, half went about 25 months or longer before their cancer grew, compared with about 15 months on letrozole alone. In people whose cancer had already grown on hormone therapy, adding palbociclib to fulvestrant raised that figure from about 5 months to about 9.5 months. In both trials, people taking palbociclib lived somewhat longer on average, but the difference in overall survival was not large enough to be statistically certain. Its proven benefit is delaying the cancer's growth, and how well it works varies from person to person. Expect frequent blood tests at first: a complete blood count before starting, at the start of each cycle, and on day 15 of the first two cycles. If counts stay in a safe range over the first six cycles, testing usually drops to about every three months. Scans at regular intervals show whether the cancer is stable, shrinking or growing. Treatment usually continues until the cancer grows or side effects become too hard to manage, and any decision to stop is made with the oncologist.

Questions to Ask Your Doctor

  1. 1.Why is palbociclib, rather than another CDK4/6 inhibitor, the right choice for my cancer?
  2. 2.Which hormone therapy or other medicines will I take with it, and how do their schedules fit together?
  3. 3.How often will I need blood tests and scans, and what results would lead us to pause treatment or lower the dose?
  4. 4.What should I do if I develop a fever, and who should I call after hours?
  5. 5.Do any of my current medicines or supplements interact with palbociclib?

Last reviewed • Oct 2026

Educational content, not medical advice.